Page last updated: 2024-10-29

isoniazid and Chemical Dependence

isoniazid has been researched along with Chemical Dependence in 21 studies

Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).

Research Excerpts

ExcerptRelevanceReference
"To determine the rate of and risk factors for discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis infection in a large, multi-site study."7.79Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis. ( Bethel, J; Colson, PW; Hirsch-Moverman, Y; Pettit, AC; Sterling, TR, 2013)
"Treatment with isoniazid in drug users appears to be safe and well tolerated, although frequent asymptomatic elevations in transaminase levels were observed."5.32Isoniazid hepatotoxicity among drug users: the role of hepatitis C. ( Fernández-Villar, A; Fluiters, E; Martínez-Vázquez, C; Mosteiro, M; Piñeiro, L; Sopeña, B; Ulloa, F; Vázquez, R, 2003)
"To determine the rate of and risk factors for discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis infection in a large, multi-site study."3.79Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis. ( Bethel, J; Colson, PW; Hirsch-Moverman, Y; Pettit, AC; Sterling, TR, 2013)
" Assuming 65% isoniazid effectiveness, and incorporating costs of screening, observed chemoprophylaxis and clinical monitoring, a net savings in tuberculosis-related hospital costs of $285,284 ($563 per person screened) was associated with DOPT ($10,274 per case prevented)."3.70Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis. ( Alcabes, P; Arno, PS; Gourevitch, MN; Wasserman, WC, 1998)
"HIV-infected adults with substance abuse (tobacco smoking, khat chewing and alcohol) should be prioritised for TB screening."1.43Determinants for tuberculosis in HIV-infected adults in Northwest Ethiopia: a multicentre case-control study. ( Alemu, YM; Awoke, W; Wilder-Smith, A, 2016)
"Treatment with isoniazid in drug users appears to be safe and well tolerated, although frequent asymptomatic elevations in transaminase levels were observed."1.32Isoniazid hepatotoxicity among drug users: the role of hepatitis C. ( Fernández-Villar, A; Fluiters, E; Martínez-Vázquez, C; Mosteiro, M; Piñeiro, L; Sopeña, B; Ulloa, F; Vázquez, R, 2003)
"Alpidem is a new anxiolytic of imidazopyridine structure which has a high affinity for the omega 1 (BZ1) modulatory site of the GABAA receptor."1.29Repeated treatment with alpidem, a new anxiolytic, does not induce tolerance or physical dependence. ( Morel, E; Perrault, G; Sanger, DJ; Zivkovic, B, 1993)
"Zolpidem is a new, short-acting hypnotic of imidazopyridine structure which binds selectively to a subpopulation of receptors involved in the action of benzodiazepines [omega 1 (BZ1) sites of the gamma-aminobutyric acidA receptors]."1.28Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic zolpidem. ( Morel, E; Perrault, G; Sanger, DJ; Zivkovic, B, 1992)

Research

Studies (21)

TimeframeStudies, this research(%)All Research%
pre-19908 (38.10)18.7374
1990's4 (19.05)18.2507
2000's3 (14.29)29.6817
2010's5 (23.81)24.3611
2020's1 (4.76)2.80

Authors

AuthorsStudies
Danna, BJ1
Harvey, AW1
Woc-Colburn, LE1
Pettit, AC1
Bethel, J1
Hirsch-Moverman, Y1
Colson, PW1
Sterling, TR2
Ricks, PM1
Hershow, RC1
Rahimian, A1
Huo, D1
Johnson, W1
Prachand, N1
Jimenez, A1
Wiebel, W1
Paul, W1
Getahun, H1
Matteelli, A1
Abubakar, I1
Aziz, MA1
Baddeley, A1
Barreira, D1
Den Boon, S1
Borroto Gutierrez, SM1
Bruchfeld, J1
Burhan, E1
Cavalcante, S1
Cedillos, R1
Chaisson, R1
Chee, CB1
Chesire, L1
Corbett, E1
Dara, M1
Denholm, J1
de Vries, G1
Falzon, D1
Ford, N1
Gale-Rowe, M1
Gilpin, C1
Girardi, E1
Go, UY1
Govindasamy, D1
D Grant, A1
Grzemska, M1
Harris, R1
Horsburgh, CR1
Ismayilov, A1
Jaramillo, E1
Kik, S1
Kranzer, K1
Lienhardt, C1
LoBue, P1
Lönnroth, K1
Marks, G1
Menzies, D1
Migliori, GB1
Mosca, D1
Mukadi, YD1
Mwinga, A1
Nelson, L1
Nishikiori, N1
Oordt-Speets, A1
Rangaka, MX1
Reis, A1
Rotz, L1
Sandgren, A1
Sañé Schepisi, M1
Schünemann, HJ1
Sharma, SK1
Sotgiu, G1
Stagg, HR1
Tayeb, T1
Uplekar, M1
van der Werf, MJ1
Vandevelde, W1
van Kessel, F1
van't Hoog, A1
Varma, JK1
Vezhnina, N1
Voniatis, C1
Vonk Noordegraaf-Schouten, M1
Weil, D1
Weyer, K1
Wilkinson, RJ1
Yoshiyama, T1
Zellweger, JP1
Raviglione, M1
Alemu, YM1
Awoke, W1
Wilder-Smith, A1
Aung, NM1
Hanson, J1
Kyi, TT1
Htet, ZW1
Cooper, DA1
Boyd, MA1
Kyi, MM1
Saw, HA1
Fernández-Villar, A2
Sopeña, B2
Vázquez, R1
Ulloa, F1
Fluiters, E1
Mosteiro, M1
Martínez-Vázquez, C1
Piñeiro, L1
Leiro, V1
Botana, M1
Douche, C1
Rougerie, M1
Perrault, G2
Morel, E2
Sanger, DJ2
Zivkovic, B2
Martin, JR1
Moreau, JL1
Jenck, F1
Pieri, L1
Gourevitch, MN1
Alcabes, P1
Wasserman, WC1
Arno, PS1
Malotte, CK1
Hollingshead, JR1
Larro, M1
Reichman, LB1
Felton, CP1
Edsall, JR1
Satpathy, R1
Das, BB1
Morrison-Smith, J1
Boehnert, MT1
Lewander, WJ1
Gaudreault, P1
Lovejoy, FH1
Brown, CV1
Stottmeier, KD1
Burkes, J1
Howard, RB1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence[NCT03302299]Phase 4302 participants (Actual)Interventional2017-04-07Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Cumulative Incidence of Participants Experiencing a Grade 3/4 Hepatotoxicity

Safety will be assessed by the occurrence of a Grade 3/4 hepatotoxicity at any time during the assigned treatment period. (NCT03302299)
Timeframe: Hepatotoxicity occurring during the six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.

Interventionpercent (Number)
INH and Vitamin B68.3

Number of Participants Who Discontinued Treatment

Lack of tolerability will be defined as any isoniazid (INH) treatment discontinuation prior to completion of the prescribed course (6 months of INH taken over a maximum period of 9 months) due to side effects or alanine transaminase (ALT)/aspartate transaminase (AST) elevations. (NCT03302299)
Timeframe: Six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.

InterventionParticipants (Count of Participants)
INH and Vitamin B632

Number of Participants With Alanine Transaminase (ALT) or Aspartate Transaminase (AST) Elevations at Study Screening

Alanine transaminase (ALT) or aspartate transaminase (AST) elevations (>2x the upper limit of normal) at study screening (NCT03302299)
Timeframe: Study screening visit

InterventionParticipants (Count of Participants)
Study Screening80

Number of Participants With Latent Tuberculosis at Study Screening.

Latent tuberculosis assessed at screening via tuberculin skin testing (TST). A TST induration >=5mm was considered positive for latent tuberculosis. (NCT03302299)
Timeframe: Study screening visit

InterventionParticipants (Count of Participants)
Study Screening308

INH Concentration in Hair: (INH Pmol + Acetyl INH Pmol) Per mg of Hair

INH concentration in hair (pmol/mg) will be measured at 3- and 6- months during INH therapy. (NCT03302299)
Timeframe: Measured at 3- and 6- months after INH initiation

Interventionpmol/mg (Median)
at 3 monthsat 6 months
INH and Vitamin B636.037.8

Percentage of Participants With Suboptimal INH Medication Adherence

Suboptimal INH adherence was defined as <90% of days with at least 1 electronic medication management (EMM) pill cap opening in the previous 90 days, at 3- and 6-months. (NCT03302299)
Timeframe: Adherence will be measured over the 6 months on INH or until INH discontinuation (whichever is shorter)

Interventionpercentage of participants (Number)
at 3 monthsat 6 months
INH and Vitamin B631.343.9

Self-reported INH Medication Adherence: Number of Days Taking INH in the Past 30 Days

"Participants were asked In the past 30 days, how many days in total have you not taken your pill? and were presented with a visual analog scale (VAS) to indicate the percentage of INH taken in the past 30 days. We converted the VAS percentage into number of days out of 30 to match the first question. Our final self-report measure was the minimum number of the 2 self-reported measurements." (NCT03302299)
Timeframe: Self-reported INH medication adherence via VAS will be measured 3- and 6- months after starting INH

Interventiondays (Median)
at 3 monthsat 6 months
INH and Vitamin B63030

Self-reported INH Medication Adherence by the Self Rating Single Item (SRSI) Scale

The Self Rating Single Item (SRSI) adherence scale asks participants to rate their ability to take their medications as prescribed over the past 30 days. Participants reporting INH use in the prior 30 days at the 3- or 6-month interview are included here, and reported their INH adherence in the prior 30 days as excellent, very good, good, fair, poor, or very poor. (NCT03302299)
Timeframe: Self-reported INH medication adherence via SRSI will be measured 3- and 6- months after starting INH

InterventionParticipants (Count of Participants)
At 3 months72558043At 6 months72558043
ExcellentVery goodGoodFairPoorVery poor
INH and Vitamin B6160
INH and Vitamin B679
INH and Vitamin B638
INH and Vitamin B62
INH and Vitamin B6124
INH and Vitamin B690
INH and Vitamin B641
INH and Vitamin B64
INH and Vitamin B60
INH and Vitamin B61

Reviews

2 reviews available for isoniazid and Chemical Dependence

ArticleYear
Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.
    The European respiratory journal, 2015, Volume: 46, Issue:6

    Topics: Antirheumatic Agents; Antitubercular Agents; Coinfection; Comorbidity; Disease Management; Drug User

2015
Advances in clinical toxicology.
    Pediatric clinics of North America, 1985, Volume: 32, Issue:1

    Topics: Antidotes; Cathartics; Charcoal; Child; Cocaine; Deglutition; Foreign Bodies; Gastric Lavage; Humans

1985

Trials

2 trials available for isoniazid and Chemical Dependence

ArticleYear
A randomized trial comparing standard outcomes in two treatment models for substance users with tuberculosis.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2015, Volume: 19, Issue:3

    Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Users; Ethambutol; Ethnicity; Female;

2015
Incentives vs outreach workers for latent tuberculosis treatment in drug users.
    American journal of preventive medicine, 2001, Volume: 20, Issue:2

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Female; Humans; Isoniazid; Male; Middle Aged; Motiva

2001

Other Studies

17 other studies available for isoniazid and Chemical Dependence

ArticleYear
Esophageal Tuberculosis - A Mass of Confusion.
    The American journal of medicine, 2020, Volume: 133, Issue:10

    Topics: Aged; Antitubercular Agents; Deglutition Disorders; Delayed Diagnosis; Diagnosis, Differential; Dire

2020
Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis.
    The Journal of infection, 2013, Volume: 67, Issue:5

    Topics: Adult; Alcohol Drinking; Antitubercular Agents; Canada; Female; Humans; Isoniazid; Latent Tuberculos

2013
Determinants for tuberculosis in HIV-infected adults in Northwest Ethiopia: a multicentre case-control study.
    BMJ open, 2016, Apr-15, Volume: 6, Issue:4

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Case-Control Studies; CD4 Lymph

2016
HIV care in Yangon, Myanmar; successes, challenges and implications for policy.
    AIDS research and therapy, 2017, Mar-04, Volume: 14, Issue:1

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; CD4 Lymphocyte Count; CD4-Posit

2017
Isoniazid hepatotoxicity among drug users: the role of hepatitis C.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Feb-01, Volume: 36, Issue:3

    Topics: Adolescent; Adult; Antitubercular Agents; Female; Hepatitis C; Humans; Isoniazid; Liver; Male; Middl

2003
Hepatitis C virus infection and isoniazid hepatotoxicity.
    Chest, 2007, Volume: 132, Issue:2

    Topics: Antitubercular Agents; Hepatitis C; Humans; Isoniazid; Liver; Prognosis; Risk Factors; Substance-Rel

2007
[Toxic optic neuritis: sometimes wrongly attributed to antituberculosis treatment (author's transl)].
    Journal francais d'ophtalmologie, 1981, Volume: 4, Issue:4

    Topics: Adult; Ethambutol; Ether; Ethyl Ethers; Female; Humans; Isoniazid; Optic Neuritis; Substance-Related

1981
Repeated treatment with alpidem, a new anxiolytic, does not induce tolerance or physical dependence.
    Neuropharmacology, 1993, Volume: 32, Issue:9

    Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Bicuculline; Carbolines; Convulsants; Diazepam; Drug

1993
Sarmazenil-precipitated withdrawal: a reliable method for assessing dependence liability of benzodiazepine receptor ligands.
    Pharmacology, biochemistry, and behavior, 1998, Volume: 59, Issue:4

    Topics: Animals; Anti-Anxiety Agents; Behavior, Animal; Benzodiazepines; Convulsants; Diazepam; Drug Toleran

1998
Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 1998, Volume: 2, Issue:7

    Topics: Antibiotic Prophylaxis; Antitubercular Agents; Cost-Benefit Analysis; Female; Humans; Isoniazid; Mal

1998
Drug dependence, a possible new risk factor for tuberculosis disease.
    Archives of internal medicine, 1979, Volume: 139, Issue:3

    Topics: Humans; Isoniazid; New York City; Risk; Substance-Related Disorders; Tuberculosis

1979
Accidental poisoning in childhood.
    Journal of the Indian Medical Association, 1979, Dec-01, Volume: 73, Issue:11

    Topics: Accident Prevention; Accidents; Adolescent; Child; Child, Preschool; Female; Household Products; Hum

1979
Rifampicin in clinical use.
    The Journal of antimicrobial chemotherapy, 1975, Volume: 1, Issue:4

    Topics: Aminosalicylic Acids; Drug Resistance, Microbial; Drug Therapy, Combination; England; Humans; Isonia

1975
Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic zolpidem.
    The Journal of pharmacology and experimental therapeutics, 1992, Volume: 263, Issue:1

    Topics: Animals; Drug Tolerance; Electroshock; Hypnotics and Sedatives; Injections, Intraperitoneal; Isoniaz

1992
Abuse of isoniazid.
    Lancet (London, England), 1972, Apr-01, Volume: 1, Issue:7753

    Topics: Humans; Isoniazid; Pyridoxine; Substance-Related Disorders

1972
Primary drug-resistant Mycobacterium tuberculosis isolated in Massachusetts in 1972.
    The Journal of infectious diseases, 1974, Volume: 130, Issue:3

    Topics: Adolescent; Adult; Aged; Alcoholism; Aminosalicylic Acids; Antitubercular Agents; Drug Resistance, M

1974
Editorial: Isoniazid toxicity.
    Minnesota medicine, 1974, Volume: 57, Issue:4

    Topics: Humans; Isoniazid; Pyridoxine; Substance-Related Disorders

1974